Risk factors for symptomatic vascular events in giant cell arteritis: a study of 254 patients with large-vessel imaging at diagnosis

被引:9
|
作者
de Mornac, Donatienne [1 ]
Agard, Christian [1 ]
Hardouin, Jean-Benoit [2 ,3 ,4 ]
Hamidou, Mohamed [1 ]
Connault, Jerome [1 ]
Masseau, Agathe [1 ]
Espitia-Thibault, Alexandra [1 ]
Artifoni, Mathieu [1 ]
Ngohou, Chan [5 ]
Perrin, Francois [6 ]
Graveleau, Julie [6 ]
Durant, Cecile [1 ]
Pottier, Pierre [1 ]
Neel, Antoine [1 ]
Espitia, Olivier [1 ]
机构
[1] CHU Nantes, Dept Internal Med, 1 Pl Alexis Ricordeau, F-44093 Nantes, France
[2] Nantes Univ, UMR 1246 SPHERE, INSERM, Nantes, France
[3] Tours Univ, Tours, France
[4] Nantes Univ Hosp, Methodol & Biostat Platform, Nantes, France
[5] Nantes Univ Hosp, Dept Med Informat, Nantes, France
[6] St Nazaire Hosp, Dept Internal Med, St Nazaire, France
关键词
aortitis; giant cell arteritis; large-vessel imaging; risk factors; vascular event; COMPLICATION AORTIC-ANEURYSM; CARDIOVASCULAR-DISEASE; TEMPORAL ARTERITIS; POPULATION; INFLAMMATION; DISSECTION; METHOTREXATE; MORTALITY; STENOSIS; PET/CT;
D O I
10.1177/1759720X211006967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To identify factors associated with vascular events in patients with giant cell arteritis (GCA). Methods: We performed a retrospective study of GCA patients diagnosed over a 20-year-period, who all underwent vascular imaging evaluation at diagnosis. Symptomatic vascular events were defined as the occurrence of any aortic event (aortic dissection or symptomatic aortic aneurysm), stroke, myocardial infarction, limb or mesenteric ischemia and de novo lower limbs arteritis stage 3 or 4. Patients with symptomatic vascular event (VE+) and without were compared, and risk factors were identified in a multivariable analysis. Results: Thirty-nine (15.4%) of the 254 included patients experienced at least one symptomatic vascular event during follow-up, with a median time of 21.5 months. Arterial hypertension, diabetes, lower limbs arteritis or vascular complication at diagnosis were more frequent in VE+ patients (p < 0.05), as an abnormal computed tomography (CT)-scan at diagnosis (p = 0.04), aortitis (p = 0.01), particularly of the descending thoracic aorta (p = 0.03) and atheroma (p = 0.03). Deaths were more frequent in the VE+ group (37.1 versus 10.3%, p = 0.0003). In multivariable analysis, aortic surgery [hazard ratio (HR): 10.46 (1.41-77.80), p = 0.02], stroke [HR: 22.32 (3.69-135.05), p < 0.001], upper limb ischemia [HR: 20.27 (2.05-200.12), p = 0.01], lower limb ischemia [HR: 76.57 (2.89-2027.69), p = 0.009], aortic atheroma [HR: 3.06 (1.06-8.82), p = 0.04] and aortitis of the descending thoracic aorta on CT-scan at diagnosis [HR: 4.64 (1.56-13.75), p = 0.006] were independent predictive factors of a vascular event. Conclusion: In this study on GCA cases with large vessels imaging at diagnosis, aortic surgery, stroke, upper or lower limb ischemia, aortic atheroma and aortitis of the descending thoracic aorta on CT-scan, at GCA diagnosis, were independent predictive factors of a vascular event.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] The current place of non-invasive large-vessel imaging in the diagnosis and follow-up of giant cell arteritis
    Liozon, E.
    REVUE DE MEDECINE INTERNE, 2020, 41 (11): : 756 - 768
  • [22] TAKAYASU ARTERITIS AND LARGE-VESSEL GIANT CELL ARTERITIS IN ITALIAN POPULATION. A RETROSPECTIVE COHORT STUDY
    Boiardi, L.
    Macchioni, P.
    Galli, E.
    Muratore, F.
    Csaali, M.
    Besutti, G.
    Spaggiari, L.
    Versari, A.
    Croci, S.
    Mancuso, P.
    Rossi, P. Giorgi
    Marvisi, C.
    Gene, G.
    Salvarani, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1567 - 1567
  • [23] Tocilizumab in Extracranial Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: A Multicentric Observational Comparative Study
    Lasa Teja, Carmen
    Loricera, Javier
    Prieto-Pena, Diana
    Lopez Gutierrez, Fernando
    Bernabeu, Pilar
    Freire Gonzalez, Mercedes
    Ferraz-Amaro, Ivan
    Castaneda, Santos
    Minguez, Mauricio
    Bravo-Mancheno, Beatriz
    Solans-Laque, Roser
    Blanco-Alonso, Ricardo
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1598 - 1600
  • [24] Disease pattern in cranial and large-vessel giant cell arteritis.
    Weyand, CM
    Brack, A
    Martinez-Taboada, V
    Stanson, A
    Goronzy, JJ
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S347 - S347
  • [25] Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease?
    Muratore, Francesco
    Kermani, Tanaz A.
    Crowson, Cynthia S.
    Koster, Matthew J.
    Matteson, Eric L.
    Salvarani, Carlo
    Warrington, Kenneth J.
    ARTHRITIS CARE & RESEARCH, 2018, 70 (09) : 1406 - 1411
  • [26] Cranial giant cell arteritis evolving into early large-vessel vasculitis
    Ghinoi, A.
    Pipitone, N.
    Nicolini, A.
    Salvarani, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (03) : S97 - S100
  • [27] Large-vessel involvement is predictive of multiple relapses in giant cell arteritis
    de Mornac, Donatienne
    Espitia, Olivier
    Neel, Antoine
    Connault, Jerome
    Masseau, Agathe
    Espitia-Thibault, Alexandra
    Artifoni, Mathieu
    Achille, Aurelie
    Wahbi, Anais
    Lacou, Mathieu
    Durant, Cecile
    Pottier, Pierre
    Perrin, Francois
    Graveleau, Julie
    Hamidou, Mohamed
    Hardouin, Jean-Benoit
    Agard, Christian
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
  • [28] COVID-19 vaccination and large-vessel giant cell arteritis
    Mungmungpuntipantip, R.
    Wiwanitkit, V
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2022, 51 (04) : 329 - 329
  • [29] Progression of large-vessel giant cell arteritis despite tocilizumab treatment
    Elfishawi, M.
    Kaymakci, M.
    Koster, M. J.
    Warrington, K. J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (04) : 984 - 985
  • [30] Normal inflammatory markers in giant cell arteritis with long-standing cranial and symptomatic large-vessel involvement
    Rodriguez-Pla, Alicia
    Naidu, Sailendra G.
    Butt, Yasmeen M.
    Davila, Victor J.
    BMJ CASE REPORTS, 2021, 14 (06)